HL
Therapeutic Areas
Polaryx Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PLX-200 | CLN2 Disease (Late-Infantile Neuronal Ceroid Lipofuscinosis) | Phase 2 |
| PLX-300 | Krabbe Disease, Niemann-Pick Type A/B, GM2 Gangliosidosis | Preclinical |
| Gene Therapy Platform | Undisclosed LSDs | Discovery |
Leadership Team at Polaryx Therapeutics
AY
Alex Yang
Chief Executive Officer
LL
Lisa L. Bollinger
Chief Medical Officer
RM
Ronald Moss
Former Chief Medical Officer
EZ
Eddy Zhu
Chief CMC Officer
GM
G. Michael Landis
Chief Financial Officer
S(
Shrijay (Jay) Vijayan
Chief Business Development Officer